Cloudreach and AWS Sign Strategic Collaboration Agreement to Accelerate Global Cloud Adoption
11.8.2021 12:00:00 EEST | Business Wire | Press release
Cloudreach, a leading independent cloud services provider, and Amazon Web Services (AWS), today unveiled a new Strategic Collaboration Agreement. The wide-ranging agreement will mean an acceleration of the companies’ joint go-to-market proposition, along with investments in Cloudreach software innovation, geographical expansion and the launch of a Talent Academy.
This agreement builds on the well-established 12-year relationship between Cloudreach and AWS. Cloudreach will expand within North America and Europe including into new territories Canada, Poland, Spain and the Nordics. In addition, Cloudreach will make significant investments in software, further developing its SMART Migration™ and SMART Modernization™ services. These services are designed to accelerate enterprise cloud adoption through intelligent automation and will help more customers to realize the benefits of AWS services with far greater efficiency.
Cloudreach CEO, Brooks Borcherding, said: “After 12 years of collaboration with AWS, we’re excited to be entering this new phase of growth. Together, we’re focused on delivering the promise of the cloud through new software-driven capabilities coupled with industry-best practices and expertise. For our customers this will mean adopting AWS cloud more efficiently and with greater confidence, achieving a faster time to value.”
Launch of Cloudreach Talent Academy
A key initiative within the agreement is the launch of a Talent Academy. The Academy is designed to train hundreds of diverse and promising candidates to become the next generation of cloud professionals. For entry into the program, Cloudreach will look for candidates with a passion for building their career in cloud, even if they do not have a technical background, and fast-track their technical development.
The program will bring more talent into the AWS community, offering candidates a path to acquire and upskill their AWS capabilities. The Talent Academy is unique in its emphasis on recruiting from a diverse pool of candidates who traditionally have not selected technical career paths. Cloudreach expects hundreds of candidates to become AWS-certified and get the hands-on experience to become cloud consultants, engineers, architects, and developers.
“Cloudreach is committed to addressing underrepresentation and the lack of diversity within the technology workforce and cloud industry. This purpose-driven investment is one of the most exciting aspects of this collaboration with AWS. We’re dedicated to be helping future professionals develop their careers where they will solve complex business challenges for our joint customers,” added Borcherding.
Doug Yeum, Head of Worldwide Channels and Alliances at AWS, said: “We are delighted to build upon the 12-year relationship with AWS Premier Partner, Cloudreach. This collaboration means AWS can bring the highest level of cloud native expertise to an even wider audience with Cloudreach, significantly accelerating the pace of global cloud adoption. We are also particularly appreciative of Cloudreach’s focus on expanding the diverse talent pool of AWS-skilled professionals, which aligns with our leadership principles as a company.”
This engagement will provide AWS and Cloudreach customers with compelling new SMART Migration™ and SMART Modernization™ service offerings to dramatically accelerate cloud adoption and reduce time-to-value by 40%. These new offerings leverage both Cloudamize, a leading planning, assessment, and migration automation software, and Sunstone, a cloud modernization machine learning engine to make continuous modernization recommendations for legacy and cloud deployed services.
Marie Measures, Chief Technology Officer at Sanne Group, the alternative asset fund administrator, said: “The possibilities are endless when you engage with an AWS Partner that’s flexible, easy to work with, and shares your organization’s values. We want to move quickly along our cloud journey and, thanks to Cloudreach and AWS, we have a well-structured transformational roadmap.”
For more details about the collaboration between AWS and Cloudreach, please visit: www.cloudreach.com/en/partners/aws-premier-consulting-partner/
– ENDS –
About Cloudreach
Cloudreach is the world’s leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation. With more than 10 years of cloud native experience, we’ve built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our work, visit www.cloudreach.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005334/en/
Contact information
Press Contact
Rahim Hakimi
Email: rahim.hakimi@cloudreach.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
